Sign up USA
Proactive Investors - Run By Investors For Investors
Why invest in AKR?
Akers Biosciences, Inc.: THE INVESTMENT CASE

Akers Biosciences funded to profitability as it gears up for transformational year

Having secured US$6.9mln of new investment, the company is now primed for growth
profit meter
INVESTMENT OVERVIEW: AKR The Big Picture
Management spoke to Proactive and is confident it will move the needle

For Akers Biosciences, Inc. (LON:AKR, NASDAQ:AKER), 2018 will be a defining year, according to chief executive John Gormally and its founder Raymond Akers.

For having secured US$6.9mln of new investment, the company is focused on becoming cash flow positive and profitable.

READ: Akers Biosciences unveils plans to raise US$6mln

The turnaround probably can’t come quickly enough for shareholders in a business currently valued at less than the cash it has in the bank.

A rerating will be effected if the company can successfully deliver on its fully-funded growth strategy set out in a 21-page Powerpoint presentation the firm delivered to would-be investors ahead of its most recent fund-raiser.

Host of other products

The cornerstone of the business will continue to be the PIFA rapid assay for an allergy to the blood thinner heparin; however, there’s a host of other products that it is hoped will help propel the company towards profitability.

Chief among them is a new rapid test for Chlamydia that has huge potential: the PIFA PLUSS assay, which can deliver results in five minutes rather than the days it takes for a lab test.

WATCH: Akers Bio sees 'material commercial growth' for Heparin allergy test

For women, at least, the simple blood test is far less invasive than the cervical swab currently used to collect samples.

“This product, we believe, is going to be transformational for the company,” says its chairman Akers.

“There is nothing like it in the world. It is the first assay that gives you the results in minutes and it is also the first blood test for Chlamydia.”

It aims to work with the organisation Planned Parenthood in the US where it will also target clinics, college campus medical centres alongside government care-givers.

Potential commercial partners

CEO Gormally said executives are lining up potential commercial partners who would help introduce PIFA PLUSS Chlamydia to the wider world; however, the product must first receive what’s called 510(k) approval from the US Food & Drug Administration.

The process of securing this regulatory sign-off began last May and the medicines watchdog asked for more data from Akers in December.

“We are nearer the end of the road with the FDA but it is very difficult to predict when it is going to happen. We think it is going to be sooner rather than later,” said Akers.

The story doesn’t end with Chlamydia. The company’s health and wellness offering also has the potential to generate significant revenues, Gormally points out.

Akers has developed an app that helps users track their health over time, which segues nicely with a number of products that tap into huge markets.

It has breath test devices that help promote, track and encourage choices related to general health and wellbeing.

Talking to network marketing companies

It is talking to network marketing companies in a bid to open new sales channels, and the plan is to target weight loss centres, health and fitness clubs and doctors specialising in anti-aging.

Sleepers in the Akers development pipeline are the PulmoHealth breath tests that detect biomarkers associated with lung cancer, asthma and chronic obstructive pulmonary disease (COPD).

The numbers involved are mind-boggling: there are 1.6mln people diagnosed each year with lung cancer, 300mln suffer asthma, while 210mln smokers are currently being treated for COPD.

An asthma clinical trial has been “highly successful” and the next step is to file with the FDA for 510(k) clearance.

Cholesterol test already on sale

Already on sale is Tri-Cholesterol, the company’s rapid test that measures total, HDL (good) and LDL (bad) cholesterol.

The product, the only one of its kind, is sold in major US drugstore chains under the FirstCheck brand and is another huge seam to mine for the business.

“This last infusion of cash will get us across the line,” says Gormally, regarding the recent fundraising.

“Everyone at Akers is supremely focused on making 2018 a profitable year.”

View full AKR profile View Profile

Akers Biosciences, Inc. Timeline

Related Articles

Frosties Box
December 04 2017
The company is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin
numerous pills
March 23 2018
Genervon is on the lookout for pharma partners to help advance its GM6 drug, which takes aim at a range of deadly diseases hitting the central nervous system
1511808112_surgeon.jpg
January 08 2018
The device can now be sold to aid in heart treatment throughout the European Union

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use